« Return to News | Awards & Advancement

Clinipace secures $15M in Series C financing

Tuesday, September 27, 2011 12:34 PM

Clinipace Worldwide has closed a $15M Series C round of funding led by Morgan Stanley Expansion Capital of San Francisco, CA.  Existing investors, including Hatteras Venture Partners of Durham, NC, and Brook Private Equity Advisors of Boston, MA, also participated in this most recent round of funding.

Clinipace Worldwide plans to use the capital to continue building its therapeutic expertise and global capacity to deliver innovative technology-amplified contract research services.

"Clinipace is an innovative company with a strong management team and a clear vision.  When we looked at the successful adoption of its service model, combined with the robust and active segment which it serves, as well as overall macro-trends in life science R&D strategies, we realized now is the perfect time for Morgan Stanley Expansion Capital to support Clinipace’s efforts to strengthen its technology leadership, therapeutic expertise, and global reach,” said Melissa Daniels, managing principal, Morgan Stanley Expansion Capital.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.